<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03751839</url>
  </required_header>
  <id_info>
    <org_study_id>EKNZ 2018-01517</org_study_id>
    <nct_id>NCT03751839</nct_id>
  </id_info>
  <brief_title>Microarchitecture, Bone Strength and Fracture Risk in Long-term Type 1 Diabetes</brief_title>
  <acronym>BOLD-1</acronym>
  <official_title>Microarchitecture, Bone Strength and Fracture Risk in Long-term Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christian Meier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single center case control study will assess differences in bone structure between women
      and men with longstanding type 1 diabetes (diabetes duration&gt;/= 25 years) and healthy
      controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on a cross-sectional approach the investigators aim to assess microstructural,
      biomechanical and densitometric bone characteristics in patients with longstanding type 1
      diabetes and age- and sex-matches controls. The investigators examine whether the presence of
      microvascular disease and/or poor diabetic control is associated with an altered bone
      microarchitecture and whether any such effect is independent of bone mineral density.
      Furthermore, the investigators aim to look into the relationship between an altered bone
      microarchitecture and advanced glycation end product (AGE) formation as well as biochemical
      markers of bone formation and bone turnover. The study aims to identify type 1 diabetic
      patients with high fracture risk by assessing the discriminatory power of parameters of
      cortical and trabecular microstructure measured via high resolution peripheral quantitative
      computed tomography (HR-pQCT) of the distal radius and tibia and high resolution quantitative
      computed tomography (HR-QCT) of the proximal femur and tibia with and without adjustment for
      bone density.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Identical diagnostic procedures will be performed in participants with type 1 diabetes and age- and sex-matched controls.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>volumetric bone mineral density in mg hydroxyapatite (HA)/ccm</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>measured by HR-pQCT at the distal radius and tibia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cortical porosity in %</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>measured by HR-pQCT at the distal radius and tibia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>bone stiffness in kilonewton (kN)/mm</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>a measure of bone strength, measured by HR-pQCT at the distal radius and tibia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>failure load in kN</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>a measure of bone strength, measured by HR-pQCT at the distal radius and tibia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>areal bone mineral density of the spine in g/cm2</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>measured by osteodensitometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>areal bone mineral density of the proximal femur in g/cm2</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>measured by osteodensitometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>areal bone mineral density of the distal radius in g/cm2</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>measured by osteodensitometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>trabecular bone score of the spine</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>a measure of bone texture, measured by osteodensitometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cortical thickness at the mid tibia in cm</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>the cortical thickness will be measured by pulse-echo ultrasound and high resolution quantitative computed tomography (HR-QCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>density weighed cortical thickness at the mid tibia in cm</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>the density weighed cortical thickness will be measured by pulse-echo ultrasound and HR- QCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone marrow adiposity in mg/cm3</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>measured by HR-pQCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of serum carboxy-terminal collagen crosslinks (CTX) in pg/ml</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>biochemical marker of bone resorption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of serum n-terminal procollagen type 1 (P1NP) in mcg/l</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>biochemical marker of bone formation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of serum pentosidine in pmol/m</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>biochemical marker associated with bone fragility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of serum carboxymethyl-lysine (CML) in pmol/ml</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>biochemical marker associated with bone fragility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of serum insulin in mU/ml</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>biochemical marker associated with bone fragility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of serum sclerostin in pg/ml</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>biochemical marker associated with bone fragility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of serum adiponectin in ng/ml</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>biochemical marker associated with bone fragility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of serum insulin like growth factor -1 (IGF1) in nM</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>biochemical marker associated with bone fragility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of serum ultrasensitive c-reactive protein (usCRP) in mg/l</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>biochemical marker associated with bone fragility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of serum interleukin 6 (IL6) in pg/ml</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>biochemical marker associated with bone fragility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of serum periostin in ng/ml</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>biochemical marker associated with bone fragility</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Diagnostic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The investigators will examine all participants in the same way by performing biochemical tests, clinical tests, osteodensitometry, HRQCT and HRpQCT measurements.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Biochemical Tests</intervention_name>
    <description>The investigators will perform blood tests in every participant.</description>
    <arm_group_label>Diagnostic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Osteodensitometry</intervention_name>
    <description>The investigators will perform an osteodensitometry in every participant.</description>
    <arm_group_label>Diagnostic</arm_group_label>
    <other_name>dual energy x-ray absorptiometry (DXA scan)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Clinical Tests</intervention_name>
    <description>The investigators perform the following clinical tests: vibration threshold test, monofilament test, chair rise test and timed up and go test in every participant.</description>
    <arm_group_label>Diagnostic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>HR-QCT</intervention_name>
    <description>The investigators will perform HR-QCT measurements of the proximal femur and tibia in every participant.</description>
    <arm_group_label>Diagnostic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>HR-pQCT</intervention_name>
    <description>The investigators will perform HR-pQCT measurements of the distal radius and distal tibia in every participant.</description>
    <arm_group_label>Diagnostic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women and men with longstanding type 1 diabetes (age 40-80 years, BMI 18-37 kg/m2 and
             age- and sex matched non-diabetic controls

          -  presence of type 1 diabetes for at least 25 years (defined by history of Insulin
             treatment)

        Exclusion Criteria:

          -  Patients unable to give written informed consent, e.g. with severe dementia or
             patients not understanding German (or other local language)

          -  Any medical or psychiatric condition which would preclude the participant from
             adhering to the protocol

          -  Idiopathic or premenopausal osteoporosis or coexisting metabolic bone disease (e.g.
             PagetÂ´s disease, primary hyperparathyroidism)

          -  Previous treatment with osteoporosis medication (bisphosphonates, denosumab) or intake
             of medications that are known to affect bone metabolism (e.g. steroids,
             anticonvulsants) within 6 months prior to enrollment

          -  Patients with medical conditions known to affect bone health ( e.g. metastatic bone
             disease, celiac disease, inflammatory bone disease, hypogonadism, thyrotoxicosis,
             hypercortisolism, chronic kidney disease stage IV and V (KDIGO), liver dysfunction
             (serum aspartate amino transferase (ASAT) &gt;3 times the upper limit of normal)

          -  Inability to keep the extremities still for a few minutes of an HR-pQCT examination
             (e.g. Parkinson disease, spastic syndrome)

          -  Pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Meier, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Meier, Prof.</last_name>
    <phone>0041612649797</phone>
    <email>christian.meier@unibas.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lilian Sewing, Dr.</last_name>
    <phone>0041612649797</phone>
    <email>Lilian.Sewing@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <state>Basel Stadt</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Meier, Prof.</last_name>
      <phone>0041612649797</phone>
      <email>christian.meier@unibas.ch</email>
    </contact>
    <contact_backup>
      <last_name>Lilian Sewing, Dr.</last_name>
      <phone>0041612649797</phone>
      <email>Lilian.Sewing@usb.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 31, 2018</study_first_submitted>
  <study_first_submitted_qc>November 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2018</study_first_posted>
  <last_update_submitted>May 3, 2020</last_update_submitted>
  <last_update_submitted_qc>May 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Basel, Switzerland</investigator_affiliation>
    <investigator_full_name>Christian Meier</investigator_full_name>
    <investigator_title>Prof. Dr. med. Christian Meier</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>In the informed consent document participants can choose whether they agree to the further use of their coded data and biochemical material for future research purposes.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

